ReviewInternational journal of molecular sciences2022
Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.Scientific reports · 2025Trial
- Juvenile Generalized Pustular Psoriasis: Management in Children-A Case Series.Clinical case reports · 2026Article
- A Narrative Review of Local Therapies in Hidradenitis Suppurativa: Treatment Landscape and Current Issues.Dermatology and therapy · 2026Review
- Lipid-Based Nanocarriers for Curcumin Delivery: A Promising Strategy in The Management of Inflammatory Diseases.International journal of nanomedicine · 2026Review
- Systematic Literature Reviews on the Disease Burden of Pediatric Psoriasis.Dermatology and therapy · 2025Review
- Oxidative Stress, High Density Lipoproteins and Hidradenitis Suppurativa: A Prospective Study.Antioxidants (Basel, Switzerland) · 2025Article
- Safety and effectiveness of ixekizumab in Japanese patients with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis: Post-marketing surveillance.The Journal of dermatology · 2025Article
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: A case report.SAGE open medical case reports · 2025Article
- Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence.Journal of clinical medicine · 2024Article
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review.Children (Basel, Switzerland) · 2024Review
- [Psoriasis in children and adolescents : Short update and guideline-based treatment].Dermatologie (Heidelberg, Germany) · 2023Review
- Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability.Patient preference and adherence · 2023Review
- [Psoriasis in children and adolescents].Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde · 2023Review
- A Practical Guide to Using Biologics in Pediatric Dermatology.Journal of cutaneous medicine and surgeryReview
- Current and emerging therapeutic strategies for amyotrophic lateral sclerosis: from pharmacological approaches to gene and stem cell therapies.Frontiers in neurologyReview
- A Case of Lip Psoriasis in a 14-Year-Old Boy Successfully Treated with Adalimumab.Case reports in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is associated with multiple comorbidities with a considerable reduction in quality of life of affected patients. One-third of psoriasis cases begin in childhood and are associated with significant medical comorbidities such as obesity, metabolic syndrome, arthritis, and psychiatric disorders. In addition, because of its chronic nature and frequent relapses, psoriasis tends to require long-term treatment. Treatment of pediatric psoriasis usually involves the same methods used for adults. However, most treatments for pediatric psoriasis are used off-label, and research in this regard is still lacking. Targeted therapies involving the use of newly developed biologic drugs are also increasingly being applied to childhood psoriasis. This review summarizes the clinical features of pediatric psoriasis and focuses mainly on the updated concepts of pathogenesis and biological treatments of pediatric psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.